These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37075669)

  • 61. Neoadjuvant Chemotherapy Increases PD-L1 Expression and CD8
    Fukuoka E; Yamashita K; Tanaka T; Sawada R; Sugita Y; Arimoto A; Fujita M; Takiguchi G; Matsuda T; Oshikiri T; Nakamura T; Suzuki S; Kakeji Y
    Anticancer Res; 2019 Aug; 39(8):4539-4548. PubMed ID: 31366557
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
    Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S
    APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Identification of immune microenvironment subtypes that predicted the prognosis of patients with ovarian cancer.
    Wang X; Li X; Wang X
    J Cell Mol Med; 2021 Apr; 25(8):4053-4061. PubMed ID: 33675171
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Correlation Between Tumor Infiltration CD8+ T-cells And PD-L1 Expression In Laryngeal Cancer And Their Prognostic Significance: Prospective Non-interventional Trial.
    Ismail M; Shakweer MM; ElWakiel H; Abd El Ghany D; Gaballah A
    Gulf J Oncolog; 2021 Sep; 1(37):23-31. PubMed ID: 35152191
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The immune microenvironment and expression of PD-L1, PD-1, PRAME and MHC I in salivary duct carcinoma.
    Xu B; Jungbluth AA; Frosina D; Alzumaili B; Aleynick N; Slodkowska E; Higgins K; Ho A; Morris L; Ghossein R; Katabi N
    Histopathology; 2019 Nov; 75(5):672-682. PubMed ID: 31237963
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
    Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
    [TBL] [Abstract][Full Text] [Related]  

  • 68. HLA-G/LILRBs: A Cancer Immunotherapy Challenge.
    Carosella ED; Gregori S; Tronik-Le Roux D
    Trends Cancer; 2021 May; 7(5):389-392. PubMed ID: 33563576
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Prognostic significance of S100A8-positive immune cells in relation to other immune cell infiltration in pre-invasive and invasive breast cancers.
    Woo JW; Chung YR; Kim M; Choi HY; Ahn S; Park SY
    Cancer Immunol Immunother; 2021 May; 70(5):1365-1378. PubMed ID: 33146829
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Concurrent High PD-L1 Expression and CD8
    Shimoda Y; Shibaki R; Yoshida T; Murakami S; Shirasawa M; Torasawa M; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Ohe Y; Motoi N
    Clin Lung Cancer; 2022 Sep; 23(6):477-486. PubMed ID: 35644780
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC).
    Farrag MS; Abdelwahab K; Farrag NS; Elrefaie WE; Emarah Z
    J Egypt Natl Canc Inst; 2021 Jul; 33(1):16. PubMed ID: 34241710
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors.
    Pawłowska A; Rekowska A; Kuryło W; Pańczyszyn A; Kotarski J; Wertel I
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446039
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma.
    Matsushita H; Hasegawa K; Oda K; Yamamoto S; Asada K; Karasaki T; Yabuno A; Nishijima A; Nejo T; Kobayashi Y; Sato S; Ikeda Y; Miyai M; Takahashi Y; Yamaguchi R; Fujiwara K; Aburatani H; Kakimi K
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461346
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Higher Numbers of T-Bet+ Tumor-Infiltrating Lymphocytes Associate with Better Survival in Human Epithelial Ovarian Cancer.
    Xu Y; Chen L; Xu B; Xiong Y; Yang M; Rui X; Shi L; Wu C; Jiang J; Lu B
    Cell Physiol Biochem; 2017; 41(2):475-483. PubMed ID: 28214872
    [TBL] [Abstract][Full Text] [Related]  

  • 76. PTPRO-related CD8
    Dong H; Xie C; Yao Z; Zhao R; Lin Y; Luo Y; Chen S; Qin Y; Chen Y; Zhang H
    Front Immunol; 2022; 13():947841. PubMed ID: 36003382
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Immunosuppressive MFAP2
    Wei R; Song J; Liu X; Huo S; Liu C; Liu X
    Cell Oncol (Dordr); 2024 Feb; 47(1):55-68. PubMed ID: 37540308
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comprehensive Analysis of Prognostic Value of MEX3A and Its Relationship with Immune Infiltrates in Ovarian Cancer.
    Zhang P; Su T; Zhang S
    J Immunol Res; 2021; 2021():5574176. PubMed ID: 34189143
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.
    Liu SY; Dong ZY; Wu SP; Xie Z; Yan LX; Li YF; Yan HH; Su J; Yang JJ; Zhou Q; Zhong WZ; Tu HY; Yang XN; Zhang XC; Wu YL
    Lung Cancer; 2018 Nov; 125():86-92. PubMed ID: 30429043
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
    Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.